VitaSpring Biomedical Co. Ltd. (VSBC) stock
VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 17, 2026Score 4/30
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical cash
Cash and short-term investments held at the end of each period.
VitaSpring Biomedical's cash was $13.37K at Jul 31, 2026. For fiscal 2026 it was $2.08K, up 666.2% from the year before. The highest annual figure on record is $107.21K in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | $2.08K | +666.2% |
| FY2025 | Jan 31, 2025 | $272 | +1992.3% |
| FY2024 | Jan 31, 2024 | $13 | -100.0% |
| FY2023 | Jan 31, 2023 | $29.66K | -72.3% |
| FY2022 | Jan 31, 2022 | $107.21K | +136.2% |
| FY2021 | Jan 31, 2021 | $45.40K | – |
| FY2020 | Jan 31, 2020 | $0 | -100.0% |
| FY2019 | Jan 31, 2019 | $105 | -98.0% |
| FY2018 | Jan 31, 2018 | $5.21K | +838.2% |
| FY2017 | Jan 31, 2017 | $555 | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ2 2026 | Jul 31, 2026 | $13.37K | +1573.0% |
| Q1 FY2027CQ1 2026 | Apr 30, 2026 | $8.17K | – |
| Q4 FY2026CQ4 2025 | Jan 31, 2026 | $2.08K | +666.2% |
| Q3 FY2026CQ3 2025 | Oct 31, 2025 | $0 | -100.0% |
| Q2 FY2026CQ2 2025 | Jul 31, 2025 | $799 | -85.5% |
| Q1 FY2026CQ1 2025 | Apr 30, 2025 | $0 | -100.0% |
| Q4 FY2025CQ4 2024 | Jan 31, 2025 | $272 | +1992.3% |
| Q3 FY2025CQ3 2024 | Oct 31, 2024 | $2.06K | -21.8% |
| Q2 FY2025CQ2 2024 | Jul 31, 2024 | $5.53K | -23.1% |
| Q1 FY2025CQ1 2024 | Apr 30, 2024 | $968 | -67.7% |
| Q4 FY2024CQ4 2023 | Jan 31, 2024 | $13 | -100.0% |
| Q3 FY2024CQ3 2023 | Oct 31, 2023 | $2.64K | -89.0% |
| Q2 FY2024CQ2 2023 | Jul 31, 2023 | $7.18K | -66.7% |
| Q1 FY2024CQ1 2023 | Apr 30, 2023 | $2.99K | -96.2% |
| Q4 FY2023CQ4 2022 | Jan 31, 2023 | $29.66K | -72.3% |
| Q3 FY2023CQ3 2022 | Oct 31, 2022 | $24.05K | -88.8% |
| Q2 FY2023CQ2 2022 | Jul 31, 2022 | $21.59K | -96.5% |
| Q1 FY2023CQ1 2022 | Apr 30, 2022 | $79.15K | -80.4% |
| Q4 FY2022CQ4 2021 | Jan 31, 2022 | $107.21K | +136.2% |
| Q3 FY2022CQ3 2021 | Oct 31, 2021 | $214.06K | +29303.4% |
| Q2 FY2022CQ2 2021 | Jul 31, 2021 | $614.06K | +84249.3% |
| Q1 FY2022CQ1 2021 | Apr 30, 2021 | $404.26K | +45169.5% |
| Q4 FY2021CQ4 2020 | Jan 31, 2021 | $45.40K | – |
| Q3 FY2021CQ3 2020 | Oct 31, 2020 | $728 | +443.3% |
| Q2 FY2021CQ2 2020 | Jul 31, 2020 | $728 | +74.2% |
| Q1 FY2021CQ1 2020 | Apr 30, 2020 | $893 | -44.9% |
| Q4 FY2020CQ4 2019 | Jan 31, 2020 | $0 | -100.0% |
| Q3 FY2020CQ3 2019 | Oct 31, 2019 | $134 | -71.4% |
| Q2 FY2020CQ2 2019 | Jul 31, 2019 | $418 | -22.2% |
| Q1 FY2020CQ1 2019 | Apr 30, 2019 | $1.62K | -50.6% |
| Q4 FY2019CQ4 2018 | Jan 31, 2019 | $105 | -98.0% |
| Q3 FY2019CQ3 2018 | Oct 31, 2018 | $468 | +20.9% |
| Q2 FY2019CQ2 2018 | Jul 31, 2018 | $537 | -42.9% |
| Q1 FY2019CQ1 2018 | Apr 30, 2018 | $3.28K | +29.1% |
| Q4 FY2018CQ4 2017 | Jan 31, 2018 | $5.21K | +838.2% |
| Q3 FY2018CQ3 2017 | Oct 31, 2017 | $387 | – |
| Q2 FY2018CQ2 2017 | Jul 31, 2017 | $941 | – |
| Q1 FY2018CQ1 2017 | Apr 30, 2017 | $2.54K | – |
| Q4 FY2017CQ4 2016 | Jan 31, 2017 | $555 | – |
See a number that looks wrong?